VERICIGUAT Drug Interactions: What You Need to Know

INTERACTIONS PDE-5 Inhibitors: Concomitant use is not recommended. ( 7.2 )

7.1 Other Soluble Guanylate Cyclase Stimulators VERQUVO is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators <span class="opacity-50 text-xs">[see Contraindications (4) ]</span> .

7.2 PDE-5 Inhibitors Concomitant use of VERQUVO with PDE-5 inhibitors is not recommended because of the potential for hypotension <span class="opacity-50 text-xs">[see Clinical Pharmacology (12.2) ]</span> .

VERQUVO is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators [see Drug Interactions (7.1) ] . VERQUVO is contraindicated in pregnancy [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ]. Patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators. ( 4 , 7.1 ) Pregnancy ( 4 )

AND PRECAUTIONS

5.1 Embryo-Fetal Toxicity Based on data from animal reproduction studies, VERQUVO may cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to a fetus. Obtain a pregnancy test before the start of treatment. Advise females of reproductive potential to use effective contraception during treatment with VERQUVO and for at least one month after the final dose <span class="opacity-50 text-xs">[see Dosage and Administration (2.2) and Use in Specific Populations (8.1 , 8.3) ]</span>.